hepatitis C

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒是患丙型肝炎高危。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙肝感染者中，重叠感染隐匿性HBV会影响干扰素疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙肝，TH1细胞活素表达显著并与肝免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿是慢性丙型肝炎（CHC）中纤维化进对抗毒治疗无应答危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化慢性丙肝（CHC）患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。